IGM Biosciences (IGMS) Jefferies London Healthcare Conference 2024 summary

Recent company updates and strategic focus

• Company is now exclusively focused on autoimmunity, with three phase 1 trials underway and a fourth about to start, all targeting large unmet needs.

• Significant research collaboration with Sanofi is ongoing, focused on IgM agonist antibodies for autoimmunity.

• Leadership changes have brought a renewed focus and strategic redesign toward maximizing success in autoimmunity.

• Pipeline includes imvotamab (CD20 x CD3), IGM-2644 (CD38 x CD3), and three undisclosed Sanofi collaboration targets.

• Company ended last quarter with $219 million in cash, providing runway into 2027.

Imvotamab program highlights and differentiation

• Imvotamab offers deep tissue B-cell depletion, supported by preclinical and clinical data.

• Demonstrates higher potency in depleting low-target expressing cells compared to rituximab.

• Wide therapeutic window established, with dosing up to 1,000 mg and no dose-limiting toxicities.

• More convenient administration than CAR T therapies, with no need for lymphodepletion or hospitalization.

• Preclinical data from ACR shows effective depletion of B-cells in tissues and periphery, outperforming ADCC antibodies.

Clinical development and data strategy

• Enrollment in phase 1 studies for RA, lupus, and myositis is progressing well, with some cohorts exceeding expectations.

• Initial data readout for imvotamab is planned for mid-2025 to ensure a robust, comprehensive dataset.

• Data will include depth and duration of B-cell depletion, safety profile, biomarker changes, and B-cell reconstitution.

• Success will be measured against rituximab, aiming for significant improvement in efficacy and safety.

• Phase 2 trials are expected to be randomized, possibly with placebo or active comparator, to quantify treatment effect.